| ANDRE, Marc |
NCT00433433 / 2005-002765-37: Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 3 | 1952 | Europe | ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual), Involved-Note Radiation Therapy, FDG-PET scan, F-18 fluorodeoxyglucose positron emission tomography scan | European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, Fondazione Italiana Linfomi ONLUS | Lymphoma | 12/11 | | | |
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/26 | 03/27 | | |
|
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 12/24 | 10/26 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
PENCIL, NCT06356740: Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 2 | 70 | Europe | Blood sample, Treatment :Abacavir 600 mg/lamivudine 300 mg, Lupus Impact Tracker questionnaire | Hospices Civils de Lyon | Systemic Lupus Erythematosus | 11/28 | 06/29 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
| Recruiting | 2 | 74 | Europe | Itacitinib, Placebo | Assistance Publique - Hôpitaux de Paris | Systemic Sclerosis | 02/26 | 02/26 | | |
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
| Recruiting | N/A | 60 | Europe | Biological sample collection | University Hospital, Clermont-Ferrand | Aseptic Abscess Syndrome | 12/24 | 12/25 | | |
NCT04220970: Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry |
|
|
| Recruiting | N/A | 150 | Europe | BIA-ALCL | The Lymphoma Academic Research Organisation | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | 06/32 | 06/32 | | |
